Unichem Laboratories demonstrates mixed financial performance. Sales growth is positive, but profit growth is inconsistent and OPM fluctuates.

Unichem's sales growth has been positive over the years. The compounded sales growth for 3 years is 11% and TTM sales growth is 15%. The compounded profit growth is 149%. Quarterly results show fluctuating OPM %, with periods of negative OPM, but recent quarters show improvement, reaching 12% in September 2024. The inconsistency in profitability raises concerns about the sustainability of its financial performance.

Capital efficiency and returns for Unichem Laboratories are weak. ROCE and ROE are negative, indicating inefficient use of capital and shareholder funds.

ROCE % has declined from 15% in 2016 to 0% in 2024. The ROE has negative values. These metrics indicate that the company is struggling to generate returns from its capital and equity. The negative returns raise concerns about the company's ability to create value for its investors. Poor capital efficiency can hinder long-term growth and sustainability.

The financial health and prudence of Unichem Laboratories is average. Debt levels are manageable, but interest coverage may be a concern given fluctuating profitability.

The Debt/Equity Ratio has remained relatively stable, with a slight increase over the years, indicating that the company's leverage is under control. However, the fluctuating profitability and periods of negative earnings could strain the company's ability to cover its interest obligations. The company's dividend payout is inconsistent. The recent trend of negative profit with no dividend payout may impact investor confidence. The company should focus on maintaining a healthy balance sheet and ensuring sufficient cash flow to meet its obligations.

The shareholding and ownership structure of Unichem Laboratories is generally positive. Promoter holding has increased significantly, indicating confidence in the company.

The increase in promoter holding from 50.93% to 70.22% demonstrates a strong commitment from the company's leadership. Institutional holding, including FIIs and DIIs, shows moderate interest. This alignment of interest between management and shareholders can have a positive impact on the company's governance and strategic direction.

The company's performance exhibits volatility, marked by fluctuations in quarterly sales, operating profit, and net profit. Such inconsistency in key financial metrics suggests potential instability in segment performance. Quarterly Sales shows increase from 291 in Sep 2021 to 462 in Sep 2024. Operating Profit Margin (OPM %) fluctuates between negative and positive values, reaching 12% in Sep 2024. Net Profit also shows significant variability from negative to positive values. These fluctuations indicate that Unichem may face challenges in maintaining consistent performance across its business segments.

Unichem Laboratories has exposure to foreign exchange and interest rate risks, as evidenced by fluctuations in other income and interest expenses. Other Income varies over the quarters, indicating sensitivity to external financial factors. Interest expenses show a gradual increase, which could impact profitability. These exposures suggest that Unichem needs to manage its financial risks effectively to mitigate potential impacts on its financial performance.

The regulatory landscape in the pharmaceutical industry is dynamic, and Unichem Laboratories faces risks associated with regulatory compliance costs. Material Cost % of Sales shows fluctuations, potentially reflecting changes in raw material prices or regulatory requirements. Employee Cost % of Sales also varies, which could be influenced by compliance-related expenses. Regulatory compliance cost trends need to be closely monitored to ensure sustainable profitability. Compliance costs may impact the company's financial performance and competitive positioning.

Working capital management at Unichem Laboratories is inefficient, as indicated by a high cash conversion cycle. Cash Conversion Cycle has increased from 57 days in Mar 2013 to 353 days in Mar 2024. Inventory Days are high and have fluctuated, indicating challenges in managing inventory levels. Debtor Days also show variability, suggesting difficulties in collecting receivables. Inefficient working capital management can lead to liquidity issues and impact operational efficiency.